Atossa Genetics Inc. (ATOS) Hit All-Time Low at $2.21 on Jun, 29

June 29, 2018 - By Noel Courtney

Atossa Genetics Inc. (NASDAQ:ATOS) Corporate Logo

Atossa Genetics Inc. (NASDAQ:ATOS) touched all time low on Jun, 29 touching $2.21. Our target is $2.06. announced it. The company has $6.22 million market cap. The company’s valuation will be $435,470 less at $2.06 target.

The stock decreased 3.07% or $0.07 during the last trading session, hitting $2.21.Atossa Genetics Inc. has volume of 123,725 shares. Since June 29, 2017 ATOS has declined 41.40% and is downtrending. ATOS underperformed by 53.97% the S&P500.

Investors expect Atossa Genetics Inc. (NASDAQ:ATOS)’s quarterly earnings on August, 13., according to RTT. Analysts have expectation on stock’s earnings per share of $-0.74. That’s up 90.36 % from last year’s $-7.68 earnings per share. Wall Street now predicts 4.23 % negative EPS growth despite Atossa Genetics Inc. previous quarter’s EPS of $-0.71.

Atossa Genetics Inc. (NASDAQ:ATOS) Ratings Coverage

In total 2 analysts cover Atossa Genetics (NASDAQ:ATOS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:ATOS) has 100% bullish analysts. 2 are the (NASDAQ:ATOS)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Friday, January 26 the stock of Atossa Genetics Inc. (NASDAQ:ATOS) earned “Buy” rating by Maxim Group.

For more Atossa Genetics Inc. (NASDAQ:ATOS) news announced briefly go to:,,, or The titles are as follows: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” announced on June 29, 2018, “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares” on June 19, 2018, “Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board” with a publish date: June 14, 2018, “Atossa Genetics (ATOS) Announces Opening of Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast …” and the last “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” with publication date: June 15, 2018.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States.The firm is valued at $6.22 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions.Currently it has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: